HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced that Jonathan Lanfear has stepped down from the role of President and Chief Executive Officer. The Board of Directors has appointed Steven Gillis, Ph.D, the company’s current Chairman of the Board, as Chairman and Acting CEO.

“We thank Jonathan for his service and leadership over the past several years and wish him the best in the future. I am honored to step in as acting CEO, and look forward to working closely with our leadership team to ensure a seamless transition and the continued development of our novel product candidates in the clinic,” said Gillis.

To learn more about HiberCell’s clinical pipeline and leadership team, visit www.HiberCell.com.